Related Experiment Video
Updated: Aug 17, 2026
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
A therapeutic area review of oncology products and players
S Fleming1, F Lucas, M Schofield
1Pope Woodhead & Associates Ltd., The Old Grammar School, 1 Ramsey Road, St Ives, Cambridge, PE27 5BZ, UK. scott.fleming@popewoodhead.co.uk
Abstract:
This article reviews the dynamics of the oncology market and treatment trends and provides strategic guidance to those concerned with new product discovery and development. Cancer is the therapeutic area of highest potential, with an annual market value expected to be in excess of US 40 billion dollars in 2020. The global incidence of cancer cases is forecast to more than double over the next 20 years. Investments in research and development will keep pace with the growing demand for effective treatments, aiming to fulfil the many and often discrete unmet medical needs. Recent breakthroughs promise more successful outcomes, particularly with the advent of more selective chemotherapy and novel therapeutic approaches. Among the latter, a number of angiogenesis inhibitors and monoclonal antibodies (mAbs) should show encouraging levels of efficacy by 2004. Oncology is a complex and high-risk therapeutic area that offers high rewards. It is appropriate for only the stronger or more focused serious players within the pharmaceutical industry. The winners will be the companies with a long-term strategic intent, a credible portfolio and engagement in appropriate alliances, particularly in discovery. The future presents ethical, clinical and commercial challenges, given the wide disparity of therapeutic outcomes among cancer patients around the world. The real success will thus be to treat cancer in innovative ways that benefit everyone and are, in volume and across the life cycle, commercially attractive to the treatment provider.
Insights
The oncology market is rapidly expanding, driven by increasing cancer incidence and demand for novel treatments. Strategic R&D and alliances are crucial for pharmaceutical companies to succeed in this high-reward, complex therapeutic area.
Area of Science:
- Oncology
- Pharmaceutical Market Analysis
- Drug Discovery and Development
Background:
- The oncology therapeutic area represents a significant market, projected to exceed $40 billion in 2020.
- Global cancer incidence is expected to more than double in the next two decades.
- Significant unmet medical needs persist within cancer treatment.
Purpose of the Study:
- To review oncology market dynamics and treatment trends.
- To provide strategic guidance for new product discovery and development in oncology.
- To identify key success factors for pharmaceutical companies in the oncology sector.
Main Methods:
- Review of market dynamics and treatment trends in oncology.
- Analysis of R&D investment and unmet medical needs.
- Assessment of novel therapeutic approaches, including angiogenesis inhibitors and monoclonal antibodies (mAbs).
Main Results:
- Oncology is a high-potential, high-risk market requiring long-term strategic commitment.
- Emerging therapies like selective chemotherapy, angiogenesis inhibitors, and mAbs show promise.
- Success hinges on credible portfolios, strategic alliances, and addressing global therapeutic outcome disparities.
Conclusions:
- The oncology market offers substantial rewards but demands focused, long-term strategies from pharmaceutical players.
- Innovation in cancer treatment is essential to meet diverse patient needs and ensure commercial viability.
- Addressing ethical, clinical, and commercial challenges is key to achieving widespread success in oncology drug development.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...